Abstract
AbstractRNA interference (RNAi) has been extensively used to downregulate abnormal excessive mRNA in treating intractable diseases like cancers. Albeit with the success of siRNA drugs, the development of shRNA (small hairpin RNA) as RNAi drugs still meets the great challenge in clinical treatments for lacking the suitable delivery vector to express numerous shRNAs in cells. Considering our previously established branch‐PCR (branched polymerase chain reaction) technology, we herein introduced a multisite‐targeting c‐Myc shRNA array into DNA nanovectors via branch‐PCR. The results indicated that this kind of DNA nanovector retained better serum stability than plasmids and linear DNA. The cell viability test further showed that the transcription of c‐Myc shRNA arrays greatly enhanced the anti‐cancer activity by eliminating approximately 98.2 % c‐Myc mRNA, which posed a technical advance in augmenting the gene silencing efficiency of vector‐expressed shRNAs in cells. Hence, it would be promising to use this customizable and stable shRNA array‐based DNA nanovectors to enhance the curable efficacy of shRNAs in cancer treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
